Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.40 USD
-0.07 (-0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $17.40 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth B Momentum C VGM
Income Statements
Fiscal Year end for Integra LifeSciences Holdings Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,542 | 1,558 | 1,542 | 1,372 | 1,518 |
Cost Of Goods | 657 | 587 | 598 | 521 | 565 |
Gross Profit | 885 | 970 | 945 | 851 | 953 |
Selling & Adminstrative & Depr. & Amort Expenses | 773 | 731 | 747 | 700 | 859 |
Income After Depreciation & Amortization | 112 | 239 | 197 | 151 | 94 |
Non-Operating Income | 21 | 25 | 68 | 14 | 20 |
Interest Expense | 51 | 50 | 50 | 72 | 54 |
Pretax Income | 81 | 214 | 215 | 94 | 60 |
Income Taxes | 13 | 33 | 46 | -40 | 10 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 68 | 181 | 169 | 134 | 50 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 68 | 181 | 169 | 134 | 50 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 241 | 364 | 324 | 295 | 209 |
Depreciation & Amortization (Cash Flow) | 130 | 125 | 127 | 144 | 115 |
Income After Depreciation & Amortization | 112 | 239 | 197 | 151 | 94 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 80.34 | 83.52 | 85.49 | 85.23 | 86.49 |
Diluted EPS Before Non-Recurring Items | 3.10 | 3.36 | 3.18 | 2.45 | 2.74 |
Diluted Net EPS (GAAP) | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 |
Fiscal Year end for Integra LifeSciences Holdings Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 418.18 | 368.87 | 397.04 | 382.42 | 381.27 |
Cost Of Goods | 192.26 | 162.04 | 170.55 | 164.08 | 174.24 |
Gross Profit | 225.92 | 206.83 | 226.49 | 218.35 | 207.03 |
SG&A, R&D, and Dept/Amort Expenses | 228.95 | 202.88 | 190.44 | 191.76 | 194.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.03 | 3.95 | 36.05 | 26.59 | 12.50 |
Non-Operating Income | 6.50 | 4.43 | 6.56 | 5.08 | 3.78 |
Interest Expense | 18.65 | 13.62 | 13.75 | 13.06 | 12.46 |
Pretax Income | -15.19 | -5.23 | 28.86 | 18.61 | 3.82 |
Income Taxes | -2.78 | -1.95 | 9.02 | -0.89 | -0.36 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -12.40 | -3.28 | 19.83 | 19.50 | 4.18 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.40 | -3.28 | 19.83 | 19.50 | 4.18 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 77.41 | 77.74 | 77.96 | 79.81 | 81.15 |
Diluted EPS Before Non-Recurring Items | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 |
Diluted Net EPS (GAAP) | -0.16 | -0.04 | 0.26 | 0.24 | 0.05 |